Nasdaq · Healthcare
REPLIGEN CORP (RGEN)
As-reported financials and recent SEC filings for REPLIGEN CORP, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$738.3M
Net income
$48.9M
Net margin
6.6%
Diluted EPS
$0.86
ROE
2.3%
P/E (TTM)
161.5×
Market cap
$8.29B
Debt / equity
0.3×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $738.3M | $634.4M | $632.4M | $801.5M | $670.5M |
| Gross profit | $386.2M | $274.6M | $278.4M | $455.7M | $391.3M |
| Operating income | $55.2M | $-35.1M | $47.7M | $224.7M | $167.2M |
| Net income | $48.9M | $-25.5M | $35.6M | $186.0M | $128.3M |
| Diluted EPS | $0.86 | $-0.46 | $0.63 | $3.24 | $2.24 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-26
View on EDGAR →1442026-06-25
View on EDGAR →42026-05-18
View on EDGAR →42026-05-18
View on EDGAR →42026-05-18
View on EDGAR →42026-05-18
View on EDGAR →42026-05-18
View on EDGAR →42026-05-18
View on EDGAR →Go deeper on RGEN
Search REPLIGEN CORP’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.